Search

Displaying results 7371 - 7380 of 7655 in total
  1. Drug

    NV-18

    go.drugbank.com/drugs/DB05886
    Experimental

    NV-18 is a product of the Novogen diphenolic synthetic analogue program that is creating drugs with diverse activities against specific types of cancer. Like phenoxodiol, NV-18 is broadly effective in the laboratory against almost all hu...

  2. Drug

    Sirna-027

    go.drugbank.com/drugs/DB05896
    Investigational

    Sirna-027 is a chemically modified short interfering RNA(siRNA) targeting Vascular Endothelial Growth Factor Receptor-1(VEGFR-1). VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway. S...

  3. Drug

    KOS-1584

    go.drugbank.com/drugs/DB05903
    Investigational

    KOS-1584 is a second-generation epothilone. Epothilones are anticancer agents with a taxane-like mechanism of action that have demonstrated activity in taxane-resistant tumors. KOS-1584 is a second-generation compound with increased pote...

  4. Drug

    NLX-P101

    go.drugbank.com/drugs/DB05924
    Experimental

    NLX-P101, gene therapy is developed by Neurologix to treat Parkinson’s disease. The gene is glutamic acid decarboxylase (GAD), whose product synthesizes the major inhibitory neurotransmitter in the brain, (gamma)-aminobutyric acid (GABA)...

  5. Drug

    Istaroxime

    go.drugbank.com/drugs/DB06157
    Investigational

  6. Drug

    Indibulin

    go.drugbank.com/drugs/DB06169
    Investigational

  7. Drug

    Paclitaxel trevatide

    go.drugbank.com/drugs/DB06171
    Investigational

    Three paclitaxel molecules linked by a cleavable succinyl ester linkage to a brain peptide vector, Angiopep-2, conjugate named ANG1005.

  8. Drug

    R112

    go.drugbank.com/drugs/DB06252
    Experimental

    R112 is an investigational compound developed to treat Allergic Rhinitis. It's mechanism of action is to inhibit SYK kinase.

  9. Drug

    MLN2704

    go.drugbank.com/drugs/DB06513
    Investigational

    A Phase 1/2 trial (NCT00070837) evaluated the safety, dosage, and pharmacokinetics of MLN2704 in patients with metastatic androgen-independent prostate cancer.

  10. Drug

    Oregovomab

    go.drugbank.com/drugs/DB04964
    Investigational

    Oregovomab is a murine monoclonal antibody that attaches to the tumor-associated antigen CA125.